Table of Contents
- Trial overview
- Cancer types being studied
- Trial phases and status
- Who can participate
- What the trials measure
- Treatment combinations in the studies
Trial overview
The available studies of Ro7247669 are testing it in cancer trials, not as a general medicine article. The trials focus on whether it can help people with different types of cancer and whether the treatment is safe in these study groups.[1][2][3][4]
All four trials listed are interventional studies, which means researchers give a treatment and then measure what happens.[1][2][3][4]
Cancer types being studied
One completed Phase 2 trial studied people with previously untreated unresectable or metastatic melanoma, which means melanoma that could not be removed by surgery or had spread to other parts of the body, and had not been treated before in this setting.[1]
Another completed Phase 1 trial studied surgically resectable hepatocellular carcinoma, which is a liver cancer that can be removed with surgery.[2]
A Phase 2 authorised trial is studying previously untreated locally advanced or metastatic urothelial cancer, meaning cancer of the urinary tract that is either locally advanced or has spread, and has not been treated before in this setting.[3]
Another authorised Phase 1 study is looking at advanced liver cancers, a broad group of later-stage liver cancer cases.[4]
Trial phases and status
The studies include both Phase 1 and Phase 2 trials.[1][2][3][4] Phase 1 trials usually focus on safety and early activity, while Phase 2 trials look more closely at how well a treatment works.[2][3][4]
Two studies are marked Completed, and two are marked Authorised.[1][2][3][4] Completed means the study has finished, while authorised means the study has been allowed to proceed.[1][2][3][4]
The enrollment numbers range from 101 to 309 participants, showing that these are medium-sized cancer studies.[1][2][3][4]
Who can participate
Each study has a specific patient group, so not everyone with cancer can join.[1][2][3][4]
People with previously untreated unresectable or metastatic melanoma could be included in the melanoma study.[1]
People with surgically resectable hepatocellular carcinoma could be included in the liver cancer surgery study.[2]
People with previously untreated locally advanced or metastatic urothelial cancer could be included in the urothelial cancer study.[3]
People with advanced liver cancers could be included in the Morpheus-Liver study.[4]
The trial data do not give full detail on all eligibility rules, so the main known factor is the cancer type and whether it is untreated, resectable, advanced, or metastatic.[1][2][3][4]
What the trials measure
The melanoma study measures progression-free survival (PFS), which is the time from randomization until the cancer gets worse or the patient dies during the treatment period or soon after treatment ends.[1]
The hepatocellular carcinoma study measures major pathologic response (MPR) rate, which means how much tumor is left in tissue after treatment and surgery.[2]
The urothelial cancer study mainly measures the incidence and severity of adverse events, which are unwanted medical problems during the study.[3]
The advanced liver cancer study measures objective response rate (ORR), adverse events, changes in vital signs, electrocardiogram (ECG) readings, and targeted laboratory test results.[4]
Treatment combinations in the studies
Ro7247669 is studied alone in some settings and with other cancer treatments in others.[1][3][4]
In the melanoma study, the brief summary says the trial is evaluating Ro7247669 at 600 mg and 1200 mg every 3 weeks, with the main focus on progression-free survival.[1]
In the hepatocellular carcinoma study, Ro7247669 is part of neoadjuvant immunotherapy combinations, meaning treatment given before surgery.[2]
In the urothelial cancer and advanced liver cancer studies, Ro7247669 is included among several immunotherapy-based combinations, showing that researchers are comparing different treatment plans rather than only one drug approach.[3][4]
